Does the CTLA4 rs3087243 (CT60) variant affect autoimmune disease risk?

The CTLA4 rs3087243 polymorphism, commonly known as CT60, is an extensively studied genetic variant that plays a significant role in modulating the risk of autoimmune disorders by influencing the body's ability to maintain immune tolerance.

Clinical and genetic evidence

Extensive research confirms that the rs3087243 variant is a significant non-HLA risk factor for multiple autoimmune conditions.

• Disease Associations: The G allele (specifically the GG and AG genotypes) is strongly linked to an increased susceptibility to Graves' disease, Type 1 Diabetes (T1D), and Rheumatoid Arthritis (RA). Meta-analyses indicate an odds ratio (OR) of approximately 1.27 for RA in certain populations.
• Disease Specificity: The variant's impact is context-dependent; while it increases risk for T1D and Graves' disease, it has been shown to be protective in ANCA-associated vasculitis (OR = 0.84), illustrating its complex role across different autoimmune phenotypes.
• Transplantation: Beyond autoimmunity, the A allele—associated with higher expression of the soluble isoform—has been linked to improved graft tolerance in organ transplant recipients, further highlighting its role in immune modulation.

Mechanistic explanations

The rs3087243 polymorphism is located in the 3' untranslated region (3' UTR) of the CTLA4 gene, where it functions as a critical regulator of gene splicing and expression.

• Isoform Splicing: This variant directly influences the alternative splicing of CTLA4 mRNA. The susceptibility-associated G allele leads to lower production of the soluble CTLA-4 (sCTLA-4) isoform compared to the A allele.
• Immune Tolerance Pathway: Soluble CTLA-4 is essential for peripheral tolerance. It functions by competitively binding to CD80/CD86 on antigen-presenting cells, thereby preventing the co-stimulation and subsequent activation of self-reactive T cells.
• Regulatory T Cell (Treg) Function: Reduced levels of sCTLA-4, as seen in carriers of the G allele, impair the suppressive capacity of Tregs and lead to diminished downregulation of dendritic cell activity. This breakdown in the T-cell mediated tolerance pathway creates a biological vulnerability that allows the immune system to attack self-antigens.

Bottom line

The CTLA4 rs3087243 (CT60) variant is a well-supported marker for autoimmune risk. By altering the production of soluble CTLA-4, it weakens the inhibitory signals required to maintain immune tolerance, particularly in carriers of the G allele, thereby increasing the likelihood of developing conditions like Graves' disease and Type 1 Diabetes.